Trade Report: Today: Syros Pharmaceuticals Inc. (SYRS) Earns Outperform Rating from Analysts at Cann

Today: Syros Pharmaceuticals Inc. (SYRS) Earns Outperform Rating from Analysts at Cann

Analysts at Cann began coverage on shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) in a research note issued on Monday, The Fly reports. The brokerage set an “outperform” rating and a $28.00 price target on the stock. Cann’s target price would suggest a potential upside of 97.32% from the stock’s previous close.

SYRS has been the topic of a number of other reports. HC Wainwright reaffirmed a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. Zacks Investment Research cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 22nd. Piper Jaffray Cos. set a $20.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, November 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $19.60.

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded down 6.06% on Monday, hitting $13.33. 18,326 shares of the stock traded hands. Syros Pharmaceuticals has a 12-month low of $8.16 and a 12-month high of $21.50. The firm’s market cap is $311.66 million. The firm’s 50-day moving average is $13.51 and its 200 day moving average is $13.07.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Monday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.11. Equities research analysts forecast that Syros Pharmaceuticals will post ($4.03) EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of SYRS. California State Teachers Retirement System purchased a new stake in Syros Pharmaceuticals during the third quarter worth about $137,000. Spark Investment Management LLC acquired a new position in shares of Syros Pharmaceuticals during the third quarter worth $160,000. Hamilton Lane Advisors LLC acquired a new position in shares of Syros Pharmaceuticals during the third quarter worth $193,000. Morgan Stanley acquired a new position in shares of Syros Pharmaceuticals during the third quarter worth $469,000. Finally, Weiss Multi Strategy Advisers LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth $832,000. Institutional investors own 54.56% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Related posts

Leave a Comment